Hikma Ventures
Overview
Founded in August 2015, Hikma Ventures (HV) operates as the corporate venture capital arm of Hikma Pharmaceuticals. HV will act as an instrument of strategic growth in broadening Hikma's offerings; our primary focus is to identify and invest in emerging companies in the digital health space, globally, that could enhance Hikma's value proposition, reputation and market intelligence. We will also consider investments in other healthcare related areas of current or future strategic interest to Hikma, including drug delivery technologies that have the potential to enhance Hikma's value chain and pipeline.\\We invest in companies at all stages of development, including start-ups, spinouts, and consortia investments. Our initial investment size is up to $3 million per round. HV looks at global opportunities but with a focus on the US and the Middle East & Africa (MEA). We seek to actively partner with the management teams of portfolio companies to realize the potential of their products and technologies.
Reach Hikma Ventures directly
Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.
Unlock full contacts →Frequently asked questions about Hikma Ventures
What stage does Hikma Ventures invest at?
Hikma Ventures backs companies at Series A.
Which regions does Hikma Ventures invest in?
Hikma Ventures invests across United States, Israel, Canada and United Kingdom.
Who are the partners at Hikma Ventures?
Team members listed for Hikma Ventures include Mazen Darwazah (Executive Vice Chairman, President of MENA) and Lana Ghanem (Managing Director).
How do I contact Hikma Ventures?
Hikma Ventures's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of its partners.
Last updated · Source: ConnectSafely investor database
